Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy

• Published in: Cancer Immunology, Immunotherapy Immunotherapy, 2023-08, Vol.72 (8), p.2717-2728
• Main Authors: Inoue, Yusuke, Inui, Naoki, Karayama, Masato, Asada, Kazuhiro, Fujii, Masato, Matsuura, Shun, Uto, Tomohiro, Hashimoto, Dai, Matsui, Takashi, Ikeda, Masaki, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Suda, Takafumi
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Agents - therapeutic use; Cancer Research; Carcinoma, Non-Small-Cell Lung - blood; Carcinoma, Non-Small-Cell Lung - drug therapy; Cytokines; Female; Humans; Immune checkpoint inhibitors; Immune Checkpoint Proteins - therapeutic use; Immunology; Interleukin 15; Interleukin 6; Interleukin-15 - blood; Interleukin-6 - blood; Lung cancer; Lung Neoplasms - blood; Lung Neoplasms - drug therapy; Male; Medical prognosis; Medicine; Medicine & Public Health; Monocyte chemoattractant protein 1; Nivolumab - therapeutic use; Non-small cell lung carcinoma; Oncology; Patients; PD-1 protein; PD-L1 protein; Platelet-derived growth factor; Prognosis; Small cell lung carcinoma
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/s00262-023-03453-z

Whether circulating levels of specific cytokines at baseline link with treatment efficacy of immune checkpoint blockade (ICB) therapy in patients with non-small cell lung cancer remains unknown. In this study, serum samples were collected in two independent, prospective, multicenter cohorts before the initiation of ICB. Twenty cytokines were quantified, and cutoff values were determined by receiver operating characteristic analyses to predict non-durable benefit. The associations of each dichotomized cytokine status with survival outcomes were assessed. In the discovery cohort (atezolizumab cohort; N  = 81), there were significant differences in progression-free survival (PFS) in accordance with the levels of IL-6 (log-rank test, P  = 0.0014), IL-15 ( P  = 0.00011), MCP-1 ( P  = 0.013), MIP-1β ( P  = 0.0035), and PDGF-AB/BB ( P  = 0.016). Of these, levels of IL-6 and IL-15 were also significantly prognostic in the validation cohort (nivolumab cohort, N  = 139) for PFS (log-rank test, P  = 0.011 for IL-6 and P  = 0.00065 for IL-15) and overall survival (OS; P  = 3.3E-6 for IL-6 and P  = 0.0022 for IL-15). In the merged cohort, IL-6 high and IL-15 high were identified as independent unfavorable prognostic factors for PFS and OS. The combined IL-6 and IL-15 status stratified patient survival outcomes into three distinct groups for both PFS and OS. In conclusion, combined assessment of circulating IL-6 and IL-15 levels at baseline provides valuable information to stratify the clinical outcome of patients with non-small cell lung cancer treated with ICB. Further studies are required to decipher the mechanistic basis of this finding.